Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)
Study context
- Population
- Patients with acute myocardial infarction (MI) who have undergone coronary angiography and have preserved ejection fraction (EF) (≥50%)about 5000 planned
- Planned comparison
- Long-term oral beta-blockade vs no beta-blockade
- Primary endpoint
- Composite of:
- All-cause death
- New non-fatal MI
Methodological detailsregistry-based, parallel, open-label, multicentre, 38 centres in Sweden, 1 in Estonia, 6 in New Zealand
- Registry-based
- Parallel
- Open-label
- Multicentre
- 38 centres in Sweden, 1 in Estonia, 6 in New Zealand
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI). Eur Heart J Cardiovasc Pharmacother. Published 13 December 2022. doi:10.
Summarised from the published abstract; every number is checked against it